Therapeutics discovery
The company seeks to discover and develop novel therapeutics that interfere with disease-causing transcriptional programs in cancer and other diseases.
Source: LinkedIn company description · Retrieved October 13, 2026
QUANTRO Therapeutics researches and develops therapeutics targeting disease-causing transcriptional programs in cancer and other diseases.
Its planned drug-discovery pipeline uses time-resolved RNA sequencing and comparative transcriptomics to identify and develop drug candidates targeting transcriptional regulators. Its initial focus is cancer-associated transcription factors described as not yet amenable to pharmacologic intervention.
Based on the company’s public LinkedIn information, supplied through RevenueBase.
The company seeks to discover and develop novel therapeutics that interfere with disease-causing transcriptional programs in cancer and other diseases.
Source: LinkedIn company description · Retrieved October 13, 2026
The pipeline employs time-resolved RNA sequencing and comparative transcriptomics to identify and develop drug candidates that interfere with transcriptional regulators.
Source: LinkedIn company description · Retrieved October 13, 2026
Supported appearances on published RevenueBase lists, including available memberships beyond displayed rankings.
Positions describe ordering within each source list. See how lists are built ↗
Embeddable award for your website
RevenueBase prepared this profile from the company’s public LinkedIn information and RevenueBase company data. These source records were retrieved on October 13, 2026. AI helped summarize these sources, with a separate automated check against the source text completed on November 4, 2026. Directory positions use company-contact counts from separate saved list snapshots dated September 19, 2026. How the company lists are built.
Share a correction, your relationship to the company, and supporting sources. Requests are reviewed before changes are published.
Explore more companies by name, headquarters and business focus.